Investment Rating - The investment rating for China Feihe (06186.HK) has been downgraded to "Recommended" due to lower-than-expected performance [2][7]. Core Views - The company is expected to achieve revenue of 9.1-9.3 billion with a year-on-year decline of 7.9%-9.9% and a net profit of 1-1.2 billion, reflecting a year-on-year decline of 36%-47% for the first half of 2025 [2][7]. - The company plans to invest no less than 1 billion in share buybacks and expects to distribute dividends of no less than 2 billion in 2025, down from 2.72 billion in the same period last year [2][7]. - The company anticipates low single-digit growth for the full year, with a projected revenue increase of 10%-15% in the second half of 2025 [7]. Financial Summary - Total revenue (million) for 2024 is projected at 20,749, with a slight increase to 20,766 in 2025, and further growth to 22,054 in 2026 [4]. - The net profit (million) is expected to decline from 3,570 in 2024 to 3,025 in 2025, before recovering to 3,602 in 2026 [4]. - Earnings per share (CNY) are forecasted to decrease from 0.39 in 2024 to 0.33 in 2025, with a gradual increase to 0.40 in 2026 [4]. Market Performance - The target price for the stock is set at 5.1 HKD, with the current price at 4.58 HKD [4][7]. - The company maintains a market capitalization of 41.5 billion HKD and a total share capital of 9.067 billion shares [5][7]. Industry Outlook - The company is expected to benefit from a recovery in newborn population growth and the implementation of fertility subsidies, which may improve industry conditions over the next 2-3 years [7]. - The company is positioned as a leading brand in the infant formula market, with a strong channel foundation and plans to launch higher-end products in the second half of 2025 [7].
中国飞鹤（06186）：业绩低于预期，加大分红回购力度